MiR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia

Leukemia Research

Volumn 38, Issue 3, 2014, Pages 402-410

  Ufkin, Melanie L ^a,b   Peterson, Sarah ^a,b   Yang, Xuehui ^b   Driscoll, Heather ^c   Duarte, Christine ^b   Sathyanarayana, Pradeep ^a,b  

^a UNIVERSITY OF MAINE   (United States)

^b Maine Medical Center Research Institute   (United States)

^c NORWICH UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle; Methylation; MicroRNA 125a; Mubritinib

Indexed keywords

APOPTOSIS; CELL CYCLE; METHYLATION; MICRORNA-125A; MUBRITINIB;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL PROLIFERATION; CPG ISLANDS; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICRORNAS; ONCOGENE PROTEINS V-ERBB; SIGNAL TRANSDUCTION;

EID: 84894254202     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.021     Document Type: Article

References (34)

1. Kluiver J., Kroesen B.J., Poppema S., van den Berg A. The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2006, 20(November (11)):1931-1936.
2. Petriv O.I., Kuchenbauer F., Delaney A.D., Lecault V., White A., Kent D., et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(August (35)):15443-15448.
3. Garzon R., Volinia S., Liu C.G., Fernandez-Cymering C., Palumbo T., Pichiorri F., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111(March (6)):3183-3189.
4. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., Valk P.J., Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111(May (10)):5078-5085.
5. Ramsingh G., Koboldt D.C., Trissal M., Chiappinelli K.B., Wylie T., Koul S., et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood 2010, 116(December (24)):5316-5326.
6. Guo S., Lu J., Schlanger R., Zhang H., Wang J.Y., Fox M.C., et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(August (32)):14229-14234.
7. Gerrits A., Walasek M.A., Olthof S., Weersing E., Ritsema M., Zwart E., et al. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood 2012, 119(January (2)):377-387.
8. Ferretti E., De Smaele E., Po A., Di Marcotullio L., Tosi E., Espinola M.S., et al. MicroRNA profiling in human medulloblastoma. International Journal of Cancer Journal International du Cancer 2009, 124(February (3)):568-577.
9. Nishida N., Mimori K., Fabbri M., Yokobori T., Sudo T., Tanaka F., et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17(May (9)):2725-2733.
10. Scott G.K., Goga A., Bhaumik D., Berger C.E., Sullivan C.S., Benz C.C. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. Journal of Biological Chemistry 2007, 282(January (2)):1479-1486.
11. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(December (4)):402-408.
12. Duan R., Pak C., Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Human Molecular Genetics 2007, 16(May (9)):1124-1131.
13. Krol J., Loedige I., Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews Genetics 2010, 9(September):597-610.
14. Treiber T., Treiber N., Meister G. Regulation of microRNA biogenesis and function. Thrombosis and Haemostasis 2012, 107(April (4)):605-610.
15. Schanen B.C., Li X. Transcriptional regulation of mammalian miRNA genes. Genomics 2011, 97(January (1)):1-6.
16. Obernosterer G., Leuschner P.J., Alenius M., Martinez J. Post-transcriptional regulation of microRNA expression. RNA 2006, 12(July (7)):1161-1167.
17. Thomson J.M., Newman M., Parker J.S., Morin-Kensicki E.M., Wright T., Hammond S.M. Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes & Development 2006, 20(August (16)):2202-2207.
18. Plass C., Oakes C., Blum W., Marcucci G. Epigenetics in acute myeloid leukemia. Seminars in Oncology 2008, 35(August (4)):378-387.
19. Claus R., Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003, 22(September (42)):6489-6496.
20. Jelovac D., Emens L.A. HER2-directed therapy for metastatic breast cancer. Oncology 2013, 27(March (3)):166-175.
21. Nagasawa J., Mizokami A., Koshida K., Yoshida S., Naito K., Namiki M. Novel HER2 selective tyrosine kinase inhibitor TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. International Journal of Urology: Official Journal of the Japanese Urological Association 2006, 5(May):587-592.
22. Kracmarova A., Cermak J., Brdicka R., Bruchova H. High expression of ERCC1, FLT1, NME4 and PCNA associated with poor prognosis and advanced stages in myelodysplastic syndrome. Leukemia & Lymphoma 2008, 49(July (7)):1297-1305.
23. Bernal T., Moncada-Pazos A., Soria-Valles C., Gutierrez-Fernandez A. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia. Experimental Hematology 2013, 41(February (2)):172-179.
24. Testa U., Riccioni R., Militi S., Coccia E., Stellacci E., Samoggia P., et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 2002, 100(October (8)):2980-2988.
25. Tettamanti S., Marin V., Pizzitola I., Magnani C.F., Giordano Attianese G.M., Cribioli E., et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. British Journal of Haematology 2013, 161(May (3)):389-401.
26. Kugler M., Stein C., Kellner C., Mentz K., Saul D., Schwenkert M., et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. British Journal of Haematology 2010, 150(September (5)):574-586.
27. Rao D.S., Hyun T.S., Kumar P.D., Mizukami I.F., Rubin M.A., Lucas P.C., et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. Journal of Clinical Investigation 2002, 110(August (3)):351-360.
28. Jin W., Wu K., Li Y.Z., Yang W.T., Zou B., Zhang F., et al. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. Oncogene 2013, 32(April (15)):1978-1987.
29. Voehringer D., van Rooijen N., Locksley R.M. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. Journal of Leukocyte Biology 2007, 81(June (6)):1434-1444.
30. DiMartino J.F., Lacayo N.J., Varadi M., Li L., Saraiya C., Ravindranath Y., et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006, 20(March (3)):426-432.
31. Giallongo C., La Cava P., Tibullo D., Barbagallo I., Parrinello N., Cupri A., et al. SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation. BMC Cancer 2013, 13:60.
32. Irwin M.E., Nelson L.D., Santiago-O'Farrill J.M., Knouse P.D., Miller C.P., Palla S.L., et al. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS ONE 2013, 8(8):e70608.
33. Martin-Subero J.I., Harder L., Gesk S., Schoch R., Novo F.J., Grote W., et al. Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia. Cancer Genetics and Cytogenetics 2001, 127(June (2)):174-176.
34. Nordigarden A., Zetterblad J., Trinks C., Green H., Eliasson P., Druid P., et al. Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice. British Journal of Haematology 2011, 155(October (2)):198-208.